Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Jul 31, 2026
Chime Financial (CHYM) Eyes +32% Upside to the $30 Analyst Target

Chime Financial (CHYM) Eyes +32% Upside to the $30 Analyst Target

Key Takeaways

  • Chime Financial stock closed at $22.60 on July 30, 2026, making the $30 target a roughly 32% climb from current levels.
  • Wall Street consensus points directly at $30 — the median and average analyst price target — with approximately 19 analysts issuing a Moderate Buy rating.
  • Strong revenue growth of 28.6% year-over-year and expanding product offerings, including Chime Plus and Chime Workplace, support the bullish case.
  • Persistent unprofitability, with a net loss of $956 million over the trailing twelve months, remains the single largest obstacle to sustained price appreciation.
  • Key technical levels to watch include support near $20 and the psychologically significant $25 zone, which has acted as resistance during recent rally attempts.
  • Investors should monitor the upcoming earnings report on August 5, 2026, as well as any progress toward narrowing losses, before forming a strong directional view.

Why the $30 Level Draws Attention

The $30 mark has emerged as the most widely cited price objective for Chime Financial (CHYM) since the company went public in June 2025. Wall Street's consensus analyst target clusters tightly around $30, with firms including Morgan Stanley, BMO Capital, Wells Fargo, and Barclays all publishing or maintaining targets at or near this threshold. That concentration of attention makes $30 more than just a round number — it represents the level where institutional analysts believe Chime's growth story would be fairly priced.

Notably, Chime shares have traded above $30 before. The stock surged roughly 60% on its first day of trading after pricing its IPO at $27, briefly touching levels above $37. The subsequent decline — shares bottomed near $15.88 earlier in 2026 — means a return to $30 would represent recovery of meaningful lost ground rather than an all-time record. The stock's 52-week range spans $15.88 to $38.67, placing $30 slightly below the midpoint of that band, which reinforces its plausibility as a near-term objective.

Company Snapshot

Chime Financial is a San Francisco-based financial technology company providing mobile-first digital banking services through its proprietary platform in partnership with FDIC-insured banks. Founded in 2013, Chime offers fee-free spending accounts, debit cards, savings products, and credit-building tools targeting consumers who earn under $100,000 annually. Its liquidity products — including SpotMe, which allows fee-free overdrafts within set limits, and MyPay, which provides early wage access — have driven strong engagement among its reported 9.1 million active members. The company generates revenue primarily through interchange fees when members use Chime-branded debit and credit cards.

Current Market Position

Chime closed at $22.60 on July 30, 2026, giving it a market capitalization of approximately $8.6 billion. The stock has gained roughly 10% over the past month, recovering from a 2026 low near $16. Yet shares remain down approximately 33% from their year-ago level and roughly 39% below the first-day closing price following the IPO. Revenue reached $2.32 billion over the trailing twelve months, representing 28.6% year-over-year growth. The company posted its first quarterly profit — earnings per share (EPS) of $0.13 — in the most recently reported quarter, beating analyst estimates of $0.03 by a wide margin.

Despite that milestone, Chime remains deeply unprofitable on an annual basis, with a trailing twelve-month net loss of approximately $956 million and a negative net margin exceeding 40%. The forward P/E ratio sits at around 57, reflecting expectations that earnings will materialize more meaningfully in 2027 and beyond. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Drive Chime Toward $30

Several catalysts support the case for a move to $30. Revenue growth north of 25% year-over-year demonstrates that Chime's member base is expanding and monetizing effectively. The launch of Chime Plus, a premium subscription tier, and Chime Workplace, an employer-focused benefits platform, open new revenue streams beyond traditional interchange fees. Inclusion in Russell indexes during 2025 has increased institutional visibility and passive fund flows.

Analyst commentary consistently highlights Chime's underappreciated monetization potential. BMO Capital initiated coverage with an Outperform rating and a $30 price target, arguing that Chime shares should "compound higher in the years ahead due to earnings upside and multiple expansion." Morgan Stanley raised its target from $30 to $31, while Canaccord Genuity maintains a Street-high $40 target. The consensus view holds that as Chime scales its member base and layers higher-margin products onto existing relationships, profitability will inflect meaningfully.

From a technical perspective, $30 sits near several important reference points. The IPO price of $27 represents a natural resistance zone that the stock has not sustainably recaptured since its initial post-IPO decline. A decisive break above $25 — an area that has capped multiple rally attempts — would likely shift momentum and bring $30 into clearer view. One thing that stands out here is how the technical setup aligns with the fundamental story.

Obstacles That Could Prevent the Move

The most significant barrier is profitability. While Chime posted a surprise quarterly profit, translating that into consistent positive earnings requires sustained operating leverage that the company has not yet proven. Ongoing investments in product development, marketing, and compliance mean expenses could continue outpacing revenue gains for several quarters.

Competition in digital banking has intensified. Traditional banks have improved their mobile offerings, and rival fintech platforms — from Block's Cash App to PayPal's Venmo — compete for the same demographic. Any compression in interchange fee economics, whether from regulatory changes or competitive pressure, would directly impact Chime's primary revenue engine.

The macroeconomic backdrop also warrants caution. Chime's core customer base — consumers earning under $100,000 — is disproportionately sensitive to economic slowdowns. A weakening labor market or reduced consumer spending would likely dampen transaction volumes and card usage, slowing revenue momentum at precisely the moment investors expect acceleration.

Analyst Opinions and Price Targets

Of the 19 to 22 analysts covering Chime Financial, the overwhelming majority rate the stock as a Buy or equivalent. The breakdown includes approximately 11 Strong Buy ratings, 5 Buy ratings, 3 to 4 Hold ratings, and 1 Sell rating. The average 12-month price target across all analysts is approximately $29.85 to $30.10, with a median of $30.00. The highest published target is $40.00 from Canaccord Genuity, while the lowest sits at $17.00. Recent adjustments have been modestly negative — BMO Capital trimmed its target from $30 to $28 in July 2026, citing questions around the transaction margin outlook — but no major firm has abandoned its Buy thesis.

Key Technical Levels

Support has formed in the $20 to $21 range, an area that held during pullbacks in June and July 2026. The 50-day moving average has trended higher since mid-June, reflecting improving short-term momentum. Resistance near $25 represents the first major test for bulls; clearing that level with conviction would place the stock at its highest point since early 2026 and likely draw momentum-oriented buyers. Beyond $25, the IPO price of $27 and the psychologically significant $30 round number form the next logical targets. On the downside, a break below $20 would raise questions about the recovery narrative and potentially expose the mid-teens, where the 52-week low sits.

Final Assessment

The $30 price target for Chime Financial appears realistic but not inevitable. The stock sits roughly 32% below that level, and the consensus of nearly two dozen Wall Street analysts supports the view that Chime's growth trajectory justifies a valuation near $30. Strong revenue expansion, a growing suite of financial products, and recent inclusion in major indexes provide tangible tailwinds. The company's first profitable quarter on an EPS basis signals that the path toward sustainable earnings is opening, albeit slowly.

However, the trajectory from $22.60 to $30 is unlikely to be straight. Persistent annual losses, fierce competition in digital banking, and the macroeconomic sensitivity of Chime's core customer base create genuine downside risks. Investors should watch the August 5 earnings report closely for evidence that revenue momentum remains intact and that management can articulate a credible path to consistent profitability. A move above $25 would mark significant technical progress, while a sustained break below $20 would challenge the recovery thesis. In either case, the $30 milestone remains a credible, analyst-backed objective — but one that likely requires both strong execution and favorable market conditions to be achieved.

Using Tickeron AI Daily Buy/Sell Signals in Practice

Navigating a stock like Chime Financial — where sentiment can shift rapidly around earnings reports, product launches, and macroeconomic data — demands constant attention. In my own process, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to monitor thousands of stocks and ETFs with AI-driven Buy, Sell, or Hold signals based on technical patterns and market conditions. This helps identify opportunities and manage positions more efficiently without tracking every data point manually. I’ve found it complements fundamental analysis well when evaluating names like CHYM.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CHYM

CHYM's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for CHYM turned positive on July 31, 2026. Looking at past instances where CHYM's MACD turned positive, the stock continued to rise in of 7 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on CHYM as a result. In of 18 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHYM advanced for three days, in of 52 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 29 cases where CHYM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHYM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CHYM broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHYM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.518) is normal, around the industry mean (28.479). P/E Ratio (5.886) is within average values for comparable stocks, (81.364). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.725). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (4.973) is also within normal values, averaging (69.517).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Shopify Inc (NASDAQ:SHOP), Salesforce (NYSE:CRM), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Adobe (NASDAQ:ADBE), Intuit (NASDAQ:INTU), Datadog (NASDAQ:DDOG), Autodesk (NASDAQ:ADSK), Workday (NASDAQ:WDAY), Atlassian Corp (NASDAQ:TEAM).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 10.31B. The market cap for tickers in the group ranges from 291 to 240.81B. SAP holds the highest valuation in this group at 240.81B. The lowest valued company is BLGI at 291.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 0%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 8%. YXT experienced the highest price growth at 62%, while NXTT experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was -22%. For the same stocks of the Industry, the average monthly volume growth was 4% and the average quarterly volume growth was -61%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 77
Price Growth Rating: 56
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
CHYM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry PackagedSoftware

Profile
Details
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.